NA
CELG

Navellier & Associates’s Celgene Corp CELG Stock Holding History

Navellier & Associates’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-409,778
Closed -$28.6M – 379
2014
Q1 		$28.6M Sell
409,778
-205,248
-33% -$16.3M 1.33% 36
2013
Q4 		$52M Buy
615,026
+597,070
+3,325% +$47.2M 2.34% 20
2013
Q3 		$1.38M Buy
+17,956
New +$1.26M 0.04% 99

Other funds holding CELG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Navellier & Associates's CELG Position: Q2 2014 in Review

Navellier & Associates sold out of Celgene Corp (CELG) in Q2 2014, closing a stake of 409,778 shares — an estimated $28.6M sold.

Navellier & Associates first reported a position in CELG in Q3 2013 and held it in 3 quarters. The position peaked at $52M in Q4 2013. 995 funds tracked by Wall St. Rank hold CELG as of Q2 2014.

  • Navellier & Associates reported no remaining Celgene Corp position as of Q2 2014 after selling out during the quarter.
  • Navellier & Associates sold 409,778 Celgene Corp shares in Q2 2014, an estimated $28.6M.
  • Navellier & Associates first reported a position in Celgene Corp in Q3 2013 and held it in 3 quarters.
  • Navellier & Associates's Celgene Corp position peaked at $52M in Q4 2013.
  • 995 funds tracked by Wall St. Rank held Celgene Corp as of Q2 2014.

Based on Navellier & Associates's 13F filing for Q2 2014, filed 9 Jul 2014.